Literature DB >> 25986721

Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future.

Francesco Merli1, Caterina Mammi, Fiorella Ilariucci.   

Abstract

Although the achievement of deep and long lasting remissions is a realistic goal of therapy in the fit patient with chronic lymphocytic leukemia (CLL), this disease typically affects elderly patients who also show one or more concomitant pathological conditions or functional limitations that have an additive effects on the reduction of patient's life expectancy and represent major limitations in the adoption of standard therapies. In these unfit but typical patients with CLL, the goals of treatment may vary from achieving good remissions without severe toxicity to simple palliation. Differently from the past when the definition of patient medical status was mainly based on age and was left to the subjective assessment of the physician, today there are several tools to define in a standardized, reproducible, and multidimensional way the initial patient assessment and to plan treatment goals in an objective way. In this review, an overview of the current approaches to the definition of the medical fitness of the patient is provided along with some practical suggestions to integrate these tools in the clinical approach to elderly patients with CLL.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986721     DOI: 10.1007/s11912-015-0454-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  53 in total

1.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Authors:  Jan A Burger; Michael J Keating; William G Wierda; Elena Hartmann; Julia Hoellenriegel; Nathalie Y Rosin; Iris de Weerdt; Ghayathri Jeyakumar; Alessandra Ferrajoli; Marylou Cardenas-Turanzas; Susan Lerner; Jeffrey L Jorgensen; Graciela M Nogueras-González; Gracy Zacharian; Xuelin Huang; Hagop Kantarjian; Naveen Garg; Andreas Rosenwald; Susan O'Brien
Journal:  Lancet Oncol       Date:  2014-08-20       Impact factor: 41.316

2.  Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century.

Authors:  Hermann Brenner; Adam Gondos; Dianne Pulte
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

3.  Comprehensive geriatric assessment 'online'.

Authors:  Len Gray; Richard Wootton
Journal:  Australas J Ageing       Date:  2008-12       Impact factor: 2.111

4.  Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study.

Authors:  Peter Crome; Frank Lally; Antonio Cherubini; Joaquim Oristrell; Andrew D Beswick; A Mark Clarfield; Cees Hertogh; Vita Lesauskaite; Gabriel I Prada; Katarzyna Szczerbińska; Eva Topinkova; Judith Sinclair-Cohen; David Edbrooke; Gary Mills
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

5.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

6.  Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience.

Authors:  Pau Abrisqueta; Arturo Pereira; Ciril Rozman; Marta Aymerich; Eva Giné; Carol Moreno; Ana Muntañola; María Rozman; Neus Villamor; Kate Hodgson; Elías Campo; Francesc Bosch; Emili Montserrat
Journal:  Blood       Date:  2009-06-24       Impact factor: 22.113

7.  Comorbidity and functional status are independent in older cancer patients.

Authors:  M Extermann; J Overcash; G H Lyman; J Parr; L Balducci
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

8.  Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  B Eichhorst; M Dreyling; T Robak; E Montserrat; M Hallek
Journal:  Ann Oncol       Date:  2011-09       Impact factor: 32.976

9.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

10.  Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.

Authors:  Arti Hurria; Constance T Cirrincione; Hyman B Muss; Alice B Kornblith; William Barry; Andrew S Artz; Linda Schmieder; Rafat Ansari; William P Tew; Douglas Weckstein; Jeffrey Kirshner; Kayo Togawa; Kurt Hansen; Vani Katheria; Richard Stone; Ilene Galinsky; John Postiglione; Harvey Jay Cohen
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.